Freeman, J, Pilling, S, Vernon, J et al. (1 more author) (2017) In vitro activities of MCB3681 and 8 comparators against Clostridium difficile isolates with known ribotypes and diverse geographical spread. Antimicrobial Agents and Chemotherapy, 61 (3). e02077-16. ISSN 0066-4804
Abstract
Treatments for Clostridium difficile infection remain limited, despite the introduction of fidaxomicin, and development of new agents is necessary. We determined the in vitro susceptibilities of 199 prevalent or emerging Clostridium difficile PCR ribotypes to MCB3681, a novel investigational quinolonyl-oxazolidinone, and 8 comparators (metronidazole, vancomycin, fidaxomicin, moxifloxacin, ciprofloxacin, clindamycin, tigecycline and linezolid). MCB3681 showed good activity against C. difficile with no evidence of MCB3681 resistance in isolates showing either or both moxifloxacin and linezolid resistance.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | (c) 2016, Freeman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Molecular Gastroenterology (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 03 Feb 2017 15:36 |
Last Modified: | 16 Jan 2018 11:03 |
Published Version: | https://doi.org/10.1128/AAC.02077-16 |
Status: | Published |
Publisher: | American Society for Microbiology |
Identification Number: | 10.1128/AAC.02077-16 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:111852 |